Amnestic Transitional Cognitive Decline in Aging and Preclinical Alzheimer's Disease

David López-Martos [1,2], Raffaele Cacciaglia [1-3], Marc Suárez-Calvet [1-4], Gemma Salvadó [1,5], Mahnaz Shekari [1,2], Armand González-Escalante [1,2], Marta Milà-Alomà [1,6,7], Anna Brugulat-Serrat [1-3,8], Carolina Minguillon [1-3], Matteo Tonietto [9], Edilio Borroni [9], Gregory Klein [9], Clara Quijano-Rubio [10], Gwendlyn Kollmorgen [11], Henrik Zetterberg [12-18], Kaj Blennow [12,13], Juan Domingo Gispert [1-3,19], Oriol Grau-Rivera [1-4]*, Gonzalo Sánchez-Benavides [1-3]*, for the ALFA study§

[1] Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
[2] Hospital del Mar Research Institute, Barcelona, Spain.
[3] Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Salud Carlos III, Madrid, Spain.
[4] Servei de Neurologia, Hospital del Mar, Barcelona, Spain.
[5] Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
[6] Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education (NCIRE), San Francisco, CA, USA.
[7] Department of Radiology, University of California, San Francisco, San Francisco, CA, USA.
[8] Global Brain Health Institute, San Francisco, CA, USA.
[9] Pharma Research and Early Development, F Hoffmann-La Roche Ltd., Basel, Switzerland.
[10] Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
[11] Roche Diagnostics GmbH, Penzberg, Germany.
[12] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.
[13] Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
[14] Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
[15] UK Dementia Research Institute at UCL, London, UK.
[16] Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.
[17] Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
[18] Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
[19] Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain.

§The complete list of collaborators of the ALFA study can be found in the acknowledgments section.

***Corresponding authors:**

Oriol Grau-Rivera, MD, PhD
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation.
Wellington 30, 08005, Barcelona, Spain
Email: ograu@barcelonabeta.org
Phone: +34 933160990

Gonzalo Sánchez-Benavides, PhD.
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation.
Wellington 30, 08005, Barcelona, Spain
Email: gsanchezb@barcelonabeta.org
Phone: +34 933160990

Abstract

INTRODUCTION: This study proposes objective, standardized criteria for defining amnestic transitional cognitive decline (aTCD) in aging and preclinical Alzheimer's disease (AD), supported by a comprehensive multimodal biomarker characterization.

METHODS: This prospective observational study analyzed 3-year longitudinal data from the Alzheimer's and Families+ cohort, including 350 cognitively unimpaired participants. The presence of aTCD was defined using robust longitudinal neuropsychological references with a multivariate base rate threshold of significant cognitive decline; its association with fluid (plasma and CSF) and neuroimaging biomarkers (PET and MRI) was evaluated using mixed-effects and voxel-wise regression models, respectively.

RESULTS: Applying the defined criteria, aTCD was identified in 35 individuals (10%), demonstrating significant associations with Core AD biomarkers (Aβ and tau) and biomarkers of non-specific processes involved in AD pathophysiology (neurodegeneration and inflammation).

DISCUSSION: These findings underscore the need for standardized clinical staging criteria to improve early detection and risk stratification in aging and preclinical AD.

KEYWORDS: Alzheimer's disease, amnestic transitional cognitive decline, clinical manifestations, multimodal biomarkers.

Introduction

Alzheimer's disease (AD) encompasses an extended preclinical stage preceding mild cognitive impairment (MCI) and dementia, characterized by underlying neuropathological changes without clinical impairment.[1] Preclinical AD has been increasingly recognized as a critical window for early detection and prevention.[2] In 2011, the National Institute on Aging and the Alzheimer's Association (NIA-AA) defined subtle cognitive decline as transitional stage between normal cognition and MCI, characterized by low cognitive performance not meeting clinical threshold.[3] The 2018 NIA-AA guidelines[4] and the 2024 Alzheimer's Association revised criteria[5] further conceptualized this stage as transitional decline (Stage 2), positioned between the asymptomatic stage (Stage 1) and the onset of cognitive impairment (Stage 3). Diagnostic guidelines specify that transitional decline should be documented by subtle, subclinical cognitive and/or behavioral decline (1-3 years), based on objective neuropsychological testing and/or subjective reports of decline. Research suggests that the most relevant manifestation of Stage 2 may be episodic memory decline, reflecting a subclinical amnestic variant in preclinical AD.[6–8] Subjective cognitive decline (SCD), however, may not adequately capture this transitional stage, as it can be absent in MCI patients with anosognosia (impaired cognitive awareness). This may limit the predictive value of SCD from the preclinical stage, where distinct metacognitive profiles, ranging from heightened to reduced cognitive awareness, can be identified.[9–11] Although the Alzheimer's Association[5] and the International Working Group[12] provided relevant conceptual frameworks, practical guidelines for standardized clinical staging remain lacking.[13,14] The absence of objective standards for defining transitional decline, Stage 2, presents a significant challenge for early detection and risk stratification.

Clinical research increasingly supports the objective conceptualization of transitional cognitive decline (TCD), reflecting growing interest in this field (see Thomas & Edmonds, 2025, for a comprehensive review).[15] These investigations aimed to establish a discrete categorization of TCD (*i.e.*, case-control paradigm); however, methodologies varied widely: ranging from single tests to composite scores, using distinct cut-offs, cross-sectional versus longitudinal designs, and spanning from clinically based to data-driven approaches. Despite substantial progress, a standardized framework for defining TCD has not yet been established. Specifically, longitudinal investigations are still relatively few and heterogeneous, and the most appropriate methods for its definition remain uncertain. Prospective studies have demonstrated that AD pathophysiology tracks with cognitive decline in the cognitively unimpaired (CU) population.[16–19] However, establishing common standards for distinguishing normal aging fluctuations from variability associated with underlying neuropathological progression remains a significant challenge.[20] Robust neuropsychological references have demonstrated higher thresholds for defining normal cognitive performance by excluding individuals demonstrating longitudinal clinical progression and/or biomarker evidence of AD pathology.[21–24] Distinguished approaches for measuring longitudinal change in clinical neuropsychology include the Reliable Change Index (RCI) and Standardized Regression-Based (SRB) models, which account for test-retest correlation, practice effects, and sociodemographic adjustments shaping intra-individual normative trajectories.[25–28] Previously, we combined these methods to develop robust biomarker-based longitudinal neuropsychological references, demonstrating greater sensitivity in detecting significant

cognitive decline, particularly in episodic memory.[29] These methods provide a standardized approach for clinical staging, particularly when combined with multivariate base rate thresholds, distinguishing significant deviation from normative frequencies of low performance across multiple neuropsychological measures.[30–34] These clinically grounded tools balance sensitivity and specificity, supporting an objective and standardized framework for defining TCD.

Building on this framework, the present study proposes criteria for defining amnestic transitional cognitive decline (aTCD) in the context of aging and preclinical AD, with implications for early detection, risk stratification, and preventive strategies. The definition of aTCD is supported by a comprehensive multimodal biomarker characterization, including Core AD biomarkers and biomarkers of non-specific processes, ranging from fluid (plasma and cerebrospinal fluid [CSF]) to neuroimaging measurements (positron emission tomography [PET] and magnetic resonance imaging [MRI]), aligned with 2024 Alzheimer's Association revised criteria.

Methods

Study Participants

This study was conducted within the Alzheimer's and Families+ (ALFA+) cohort, a longitudinal extension of the ALFA parent cohort at the Barcelonaβeta Brain Research Center, Barcelona, Spain.[35] The ALFA cohort recruited CU individuals aged 45–74 years, free from major medical, psychiatric, or neurological conditions. The ALFA+ cohort represents a selected subset of ALFA participants enriched for AD risk factors, including parental history of AD and carriage of the apolipoprotein E (*APOE*) ε4 allele. Eligibility criteria for ALFA+ included prior participation in ALFA, age 45–65 years at enrollment, and willingness to undergo comprehensive procedures, including clinical and neuropsychological assessment, blood and CSF collection, as well as MRI and PET imaging. Participants with cognitive impairment, systemic illnesses, or a known monogenic AD mutation were excluded. Full details are provided in the Supplementary Material (see Supplementary Methods).

In this study, we included 350 CU participants from ALFA+ with available baseline CSF biomarker determination and longitudinal neuropsychological evaluations (two visits over a 3-year follow-up). Individuals with normal CSF biomarker profiles or within the AD *continuum* were retained, whereas individuals with suspected non-AD pathology were excluded, according to the AT(N) classification system. Selection criteria for this study are consistent with previous work in the ALFA+ cohort, as previously described. [29]

The ALFA+ study (ALFA-FPM-0311) was approved by the independent ethics committee 'Parc de Salut Mar', Barcelona, registered at Clinicaltrials.gov (identifier: NCT02485730). All participants signed the study's informed consent form approved by the independent ethics committee 'Parc de Salut Mar', Barcelona.

Biomarker Measurements

Plasma and Cerebrospinal Fluid (CSF)

Participants were invited to undergo longitudinal collection of CSF and blood for biomarker analysis. CSF biomarkers included Aβ42/40, p-tau181, total tau (t-tau), p-tau181/Aβ42, NfL, and GFAP. Plasma biomarkers included p-tau217, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). Samples were collected on the same day under fasting conditions in both baseline and follow-up visits following standard protocols previously described.[36,37] All biomarkers, except for plasma p-tau217, were analyzed at the Clinical Neurochemistry Laboratory at the University of Gothenburg, Sweden. Plasma p-tau217 was measured by Eli Lilly and Company using a previously published in-house assay on the Meso Scale Discovery (MSD) platform.[38] CSF Aβ42/40, NfL, and GFAP, as well as plasma NfL and GFAP were quantified with the NeuroToolKit, a panel of prototype immunoassays, using electrochemiluminescence Elecsys® immunoassays on fully automated Cobas® e 411 or e 601 modules (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). CSF p-tau181 and t-tau were measured with the Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF immunoassays, respectively, on the Cobas e 601 module. CSF p-tau181/Aβ42 was measured using the Elecsys electrochemiluminescence immunoassay on the Cobas e 601 module.

Positron Emission Tomography (PET)

Participants were invited to undergo longitudinal Aβ PET scans, and a subset was invited to undergo cross-sectional tau PET scans at follow-up. Scans were acquired on a Siemens Biograph mCT scanner, following a cranial CT for attenuation correction. Aβ PET scans (~185 MBq [^{18}F]flutemetamol) were acquired 90–110 min post-injection (20 min, 4 × 5 min frames), and tau PET scans (368.75 MBq ± 13.02 [^{18}F]RO948) were acquired 70–90 min post-injection. Images were reconstructed using ordered subset expectation maximization (OSEM) with time-of-flight and point spread function modeling (Aβ: 8 iterations, 21 subsets, 3 mm; tau: 4 iterations, 21 subsets, 4 mm). All PET scans were co-registered to corresponding T1-weighted MRI, spatially normalized to MNI space using MRI-derived DARTEL transformations. Normalized voxel intensities were computed as Standardized Uptake Value Ratio (SUVR), using the whole cerebellum as the reference region for Aβ PET, and the inferior cerebellum for tau PET. Longitudinal changes in Aβ PET load were computed voxel-wise in normalized space (SUVR change from baseline). Spatially normalized images were smoothed with an 8-mm full-width at half maximum (FWHM) Gaussian kernel. Additionally, for Aβ PET, Centiloid values were quantified using a validated in-house pipeline using the standard Centiloid target region.[39]

Magnetic Resonance Imaging (MRI)

Participants were invited to undergo longitudinal MRI scans. T1-weighted 3D-turbo field echo sequences were acquired with a 3T Philips Ingenia CX scanner (voxel size = 0.75 mm^3 isotropic; field of view = 240 × 240 × 180 mm^3; flip angle = 8°; repetition time = 9.9 ms; echo time = 4.6 ms; inversion time = 900 ms). Grey matter (GM) was segmented using the Statistical Parametric Mapping software (SPM 12, Wellcome Department of Imaging Neuroscience, London, UK) and mapped into a common space for subsequent normalization with a 12-parameter affine transformation. GM segmentations were used to generate a template, which was warped into standard MNI space using the high-dimensional DARTEL toolbox.[40] Resulting flow fields and normalization parameters were applied to normalize the native GM images to MNI space. To preserve the native local GM volume (GMv), a modulation step was applied, multiplying voxel intensities by the Jacobian determinants derived from the normalization procedure.[41] Quality control of normalization was performed with the Computational Anatomy Toolbox (CAT 12), confirming no registration errors. Longitudinal changes in GMv were computed voxel-wise using SPM's pairwise longitudinal registration, a high-dimensional warping framework applied in native space. This procedure generated Jacobian maps encoding local expansions or contractions, which were then normalized in MNI space using DARTEL. Spatially normalized images were smoothed with an 8-mm FWHM Gaussian kernel. Total intracranial volume (TIV) was computed as the sum of GM, white matter (WM), and CSF volumes.

Multimodal Biomarker Panel and Classification System

According to previous work in the ALFA+ cohort, the AT(N) classification system was used to define biomarker profiles in consistency with the 2018 NIA-AA research framework.[4]

CSF biomarker classification was determined using previously validated cut-offs in the ALFA+ cohort: Aβ-positivity (A+) was defined by Aβ42/40 ratio < 0.071, tau-positivity (T+) by p-tau181 > 24 pg/mL, and neurodegeneration-positivity ([N]+) by t-tau > 300 pg/mL.[36] Following 2024 Alzheimer's Association revised criteria,[5] this study focused on Core AD biomarkers and biomarkers of non-specific processes involved in AD pathophysiology, including plasma, CSF, PET, and MRI biomarker measurements. Full details are provided in the Supplementary Material (see Tables S1 and S2).

Neuropsychological Measurements

Administration Procedure

Participants were invited to undergo longitudinal neuropsychological assessments. Episodic memory was assessed using the Free and Cued Selective Reminding Test (FCSRT), the Memory Binding Test (MBT), and the Wechsler Memory Scale–IV (WMS-IV) Logical Memory (LM) Subtest. In total, 11 episodic memory variables were included: 4 main variables from the FCSRT, 4 main variables from the MBT, and 3 main variables from the WMS-IV LM Subtest. Global cognition was screened with Clinical Dementia Rating (CDR) and Mini Mental State Examination (MMSE). SCD was assessed with the Subjective Cognitive Decline Questionnaire (SCD-Q). Neuropsychological assessments were conducted over two sessions, at both baseline and follow-up visits, with sessions separated by approximately three months. For each visit, the FCSRT, WMS-IV LM subtest, CDR, MMSE, and SCD-Q were administered in the first session, while MBT was administered in the second session. Administration procedure was consistent across baseline and follow-up visits.

Tests and Questionnaires

Free and Cued Selective Reminding Test (FCSRT):

The Spanish FCSRT was used to assess episodic memory employing a controlled learning procedure.[42] Participants learned 16 semantically unrelated words paired with cues and completed three recall trials, each preceded by a 20-second subtraction task. Trials included free recall followed by cued recall for unrecalled items, with selective reminding applied only in the first two trials. Delayed free and cued recall was assessed after 25–35 minutes. Variables of interest included total free immediate recall (0–48), total immediate recall (0–48), total free delayed recall (0–16), and total delayed recall (0–16).

Memory Binding Test (MBT):

The Spanish MBT was used to assess episodic memory employing an associative learning procedure.[43] Participants learned two lists of 16 semantically paired words under controlled conditions, followed by recall of each list by semantic category and free recall of all 32 items. Delayed recall (free and facilitated) was tested after 30 minutes. Variables of interest included total immediate free recall (0–32), total immediate paired recall (0–32), total delayed free recall (0–32), and total delayed paired recall (0–32).

Wechsler Memory Scale–IV (WMS-IV) Logical Memory (LM) Subtest:

The Spanish WMS-IV LM subtest was used to assess narrative episodic memory.[44] Participants immediately recalled two orally presented stories (B and C), recalled them after 20–30 minutes, and then completed a recognition task. Variables of interest included immediate recall (0–50), delayed recall (0–50), and recognition (0–30).

Clinical Dementia Rating (CDR):

The Spanish CDR was used to screen global cognition and daily functioning across six domains, yielding a global score from 0 (no impairment) to 3 (severe dementia).[45]

Mini Mental State Examination (MMSE):

The Spanish MMSE was used to screen global cognition, assessing orientation, registration, attention, recall, language, and constructive praxis (0–30).[46]

Subjective Cognitive Decline Questionnaire (SCD-Q):

The Spanish SCD-Q was used to assess SCD, completed by both participant and study partner, independently.[47] The questionnaire contains three initial yes/no items and 24 questions on everyday cognitive difficulties. Categorically defined SCD status was determined according to the first item ("Do you perceive memory or cognitive difficulties?" for participants; "Do you perceive he/she has cognitive or memory difficulties?" for study partners). Total scores quantified SCD (0–24).

Clinical Staging

Amnestic Transitional Cognitive Decline (aTCD):

aTCD was defined using a longitudinal, multi-criteria psychometric approach selected to enhance diagnostic sensitivity and specificity. Participants were required to meet the following criteria: significant cognitive decline across multiple episodic memory measures (FCSRT, MBT, and WMS-IV LM), operationalized as AD biomarker-based complex SRB change < -1.645 SD per variable. Complex SRB change indices were referenced to the Aβ-negative group and were adjusted for age, sex, and education according to previously validated robust longitudinal neuropsychological references in the ALFA+ cohort.[29] A multivariate base rate threshold was applied to categorically determine the presence of aTCD. Participants with ≥10 measures were required to show decline on ≥3 measures, and those with <10 measures were required to show decline on ≥2 measures.[33] All 350 participants had complete longitudinal measures for the FCSRT. Full details are provided in the Supplementary Material (see Supplementary Methods and Supplementary Results, Tables S3 and S4).

Amnestic Mild Cognitive Impairment (aMCI):

aMCI was defined at both baseline and follow-up using a cross-sectional, multi-criteria psychometric approach selected to enhance diagnostic specificity. Participants were required to meet the following criteria: CDR global score > 0; MMSE score < 27, and the conservative application of the neuropsychological criteria for aMCI,[48] operationalized as performance < 1.65 SD below the conventional normative mean on at least 2 of 4 main measures from the FCSRT.

Statistical Analysis

Fluid Biomarkers

Associations between aTCD and fluid biomarkers (plasma and CSF) were evaluated using linear mixed-effects (LME) regression models implemented with the lme4 package (R 4.2.1, RStudio 2022.07.1). Models included two time points (baseline and follow-up), with log10-transformed fluid biomarkers entered as outcomes in independent models and group classification (0: Stable, 1: aTCD) as the main predictor, adjusting for age, sex, *APOE-ε4*, and time. Models included a group × time interaction and a random intercept for participant. Time was coded categorically (baseline vs. follow-up) for direct group comparison of within-subject change, with age modeled as a time-varying covariate to account for the exact variability in longitudinal time interval across participants. Results were reported including standardized β coefficients with 95% confidence intervals, *p*-values, marginal and conditional R^2 (*i.e.*, variance explained by fixed effects alone and by both fixed and random effects, respectively), and the Akaike Information Criterion (AIC). Nominal *p*-values < 0.05 were considered statistically significant.

Neuroimaging Biomarkers

Associations between aTCD and neuroimaging biomarkers were evaluated using voxel-wise fixed-effects regression models implemented with SPM 12 (MATLAB 2022b). PET and MRI GMv neuroimaging data were entered as outcomes in independent models, with group classification (0: Stable, 1: aTCD) as the main predictor, adjusting for age, sex, *APOE-ε4*, TIV (for MRI GMv analyses), and follow-up time interval measured in years (for longitudinal analyses). Voxel-wise neuroimaging models employed an explicit GM mask, further excluding the cerebellum. Results were considered significant at nominal *p*-values < 0.005 with a cluster-extent threshold > 100 voxels. Statistical results were reported at both the cluster and peak levels, including cluster size (k), *p*-value, *T*-value, and peak MNI coordinates (x, y, z), alongside corresponding anatomical labels at the cluster-level, using 1 mm^3 resolution labeling from the Automated Anatomical Labelling Atlas 3. Full details are provided in the Supplementary Material (see Table S5).

Exploratory Analysis

Longitudinal GMv changes were extracted at the cluster level from regions of interest (ROIs) defined based on post-hoc group-level contrasts, using MarsBaR 0.45 (MATLAB 2022b). Within the aTCD group, associations of fluid biomarkers with longitudinal GMv changes by ROIs were evaluated using fixed-effects linear regression models (RStudio). Longitudinal GMv change values within ROIs, computed as the sum of mean values from each cluster, subsequently normalized for TIV, were entered as outcomes, with log10-transformed fluid biomarkers (baseline and longitudinal change) as the primary predictors in independent models, adjusting for age, sex, and follow-up time interval measured in years (for longitudinal analyses). Statistical results were reported including standardized β coefficients with 95% confidence intervals, nominal and adjusted R^2, *p*-values, and AIC. Nominal *p*-values < 0.05 were considered statistically significant. Full details are provided in the Supplementary Material (see Table S6).

Results

Characteristics of the Participants

A total of 350 CU participants were included in the present study, with a mean longitudinal time interval of 3.30 years (standard deviation = 0.52). According to the clinical staging criteria, 315 individuals (90%) were classified as stable, and 35 (10%) as aTCD, with no participant fulfilling criteria for aMCI. Baseline characteristics of the full sample and division by groups are presented in **Table 1**.

Significant baseline differences were found between stable and aTCD groups. The group exhibiting aTCD was slightly older (p-value < 0.001), demonstrated a greater prevalence of Aβ positivity (p-value = 0.002), higher plasma p-tau217 concentration (p-value = 0.009), higher CSF p-tau181/Aβ42 ratio (p-value < 0.001), higher Aβ PET load (p-value < 0.001), lower performance on MMSE (p-value = 0.048) and greater SCD-Q scores, considering both self-reported (p-value = 0.004) and study-partner reports (p-value = 0.003), independently. No significant baseline differences were found for sex, education, *APOE-ε4* status, and categorically defined SCD status, considering both self-reported and study-partner reports, independently. Within the subset of aTCD, categorically defined self-reported SCD was present in 15 out of 35 individuals (43%) at baseline, increasing to 20 out of 35 individuals (57%) at follow-up.

Table 1. Baseline Characteristics of the Participants

Characteristics	Full Sample, n= 350 (100%)	Stable, n= 315 (90%)	aTCD, n= 35 (10%)	*p*-value
Demographic				
Age, mean (SD)	60.93 (4.72)	60.59 (4.62)	63.94 (4.61)	**< 0.001**
Female sex, n (%)	211 (60.29)	191 (60.63)	20 (57.14)	0.827
Education (years), mean (SD)	13.53 (3.48)	13.59 (3.46)	12.91 (3.66)	0.274
Genetic				
APOE-ε4 carriers, n (%)	191 (54.57)	169 (53.65)	22 (62.86)	0.390
Biomarkers				
Aβ-positive status, n (%)	122 (34.86)	101 (32.06)	21 (60)	**0.002**
Plasma p-tau217 (pg/ml), mean (SD)	0.153 (0.090)	0.149 (0.087)	0.191 (0.107)	**0.009**
CSF p-tau181/Aβ42 (hybrid ratio), mean (SD)	0.014 (0.011)	0.013 (0.082)	0.024 (0.022)	**< 0.001**
Aβ PET (Centiloids), mean (SD)	3.52 (17.25)	1.77 (14.77)	18.93 (27.44)	**< 0.001**
Neuropsychology				
MMSE, mean (SD)	29.18 (0.92)	29.21 (0.90)	28.89 (1.05)	**0.048**
SCD Participant, positive status, n (%)	98 (28)	83 (26.35)	15 (42.86)	0.062
SCD-Q Participant, total, mean (SD)	4.11 (4.38)	3.88 (4.25)	6.18 (5.08)	**0.004**
SCD Study Partner, positive status, n (%)	16 (4.57)	12 (3.81)	4 (11.43)	0.064
SCD-Q Study Partner, total, mean (SD)	1.53 (2.47)	1.40 (2.33)	2.71 (3.26)	**0.003**

Results presented correspond to the mean and standard deviation (SD) for continuous variables and number of observations (n) and percentage (%) for categorical variables. Comparisons between stable and aTCD groups were performed using ANOVA, chi-square (χ^2), or Fisher's Exact Test, depending on the type of variable and distribution of the data, with corresponding nominal *p*-values reported. aTCD was defined using robust longitudinal neuropsychological references with a multivariate base rate threshold of significant cognitive decline. Episodic memory was evaluated with standardized neuropsychological tests (Free and Cued Selective Reminding Test; Memory Binding Test; WMS-IV: Logical Memory Subtest). The previously validated biomarker cut-off used to define Aβ-positive status in the ALFA+ cohort was < 0.071 for the CSF Aβ42/40 ratio. Bold text indicates a significant association (*p*-values < 0.05). Aβ: β-amyloid; APOE: apolipoprotein E; aTCD: amnestic transitional cognitive decline; CSF: cerebrospinal fluid; MMSE: mini-mental state examination; PET: positron emission tomography; p-tau: phosphorylated tau; SCD: subjective cognitive decline; SCD-Q: subjective cognitive decline questionnaire.

Associations of aTCD with Fluid Biomarkers

Significant results were observed for the association of aTCD with fluid biomarkers. Results are presented in **Table 2** and **Figure 1.**

Considering Core AD biomarkers, aTCD was associated with higher plasma p-tau217 concentration (β_{STD}[95%CI]= 0.409 [0.123, 0.686]), higher CSF p-tau181/Aβ42 ratio (β_{STD}[95%CI]= 0.637 [0.322, 0.953]), and greater longitudinal increases of CSF p-tau181/Aβ42 ratio over time (β_{STD}[95%CI]= 0.219 [0.053, 0.384]), compared to the stable group.

Considering biomarkers of non-specific processes involved in AD pathophysiology, aTCD was associated with higher plasma NfL concentration (β_{STD}[95%CI]= 0.400 [0.076, 0.723]), higher CSF NfL concentration (β_{STD}[95%CI]= 0.348 [0.058, 0.638]), higher plasma GFAP concentration (β_{STD}[95%CI]= 0.564 [0.262, 0.865]), and higher CSF GFAP concentration (β_{STD}[95%CI]= 0.324 [0.0.027, 0.621]), compared to the stable group.

Table 2. Associations of aTCD with Fluid Biomarkers

Model outcome	n	Predictors	β_{STD} (95% CI)	*p*-value	R^2	AIC
Core AD biomarkers						
Plasma p-tau217	349/338				0.400/0.676	-575.01
		Group	0.409 (0.132, 0.686)	**0.004**		
		Time	1.128 (1.024, 1.231)	**< 0.001**		
		Group x Time	0.078 (-0.204, 0.361)	0.586		
CSF p-tau181/Aβ42	350/264				0.235/0.917	-593.193
		Group	0.637 (0.322, 0.953)	**< 0.001**		
		Time	0.304 (0.223, 0.386)	**< 0.001**		
		Group x Time	0.219 (0.053, 0.384)	**0.010**		
Biomarkers of non-specific processes involved in AD pathophysiology						
Plasma NfL	348/333				0.180/0.512	-407.404
		Group	0.400 (0.076, 0.723)	**0.016**		
		Time	0.244 (0.118, 0.370)	**< 0.001**		
		Group x Time	-0.333 (-0.683, 0.018)	0.063		
CSF NfL	350/264				0.343/0.887	-988.165
		Group	0.348 (0.058, 0.638)	**0.019**		
		Time	0.367 (0.284, 0.450)	**< 0.001**		
		Group x Time	0.029 (-0.161, 0.220)	0.762		
Plasma GFAP	348/333				0.303/0.880	-832.058
		Group	0.564 (0.262, 0.865)	**< 0.001**		
		Time	0.420 (0.338, 0.502)	**< 0.001**		
		Group x Time	-0.075 (-0.251, 0.100)	0.400		
CSF GFAP	350/264				0.318/0.950	-1228.204
		Group	0.324 (0.027, 0.621)	**0.033**		
		Time	0.744 (0.672, 0.815)	**< 0.001**		
		Group x Time	0.068 (-0.060, 0.196)	0.299		

Results from mixed-effects regression models indicating model outcome, number of observations (n) at baseline/follow-up, standardized (STD) β coefficients, 95% Confidence Intervals (CI), nominal *p*-values, marginal/conditional R^2, and Akaike Information Criteria (AIC) measurements. The mixed-effects regression models used two time-points and included a random intercept for each participant. The structure of the independent models was the following: Biomarker ~ Age + Sex [0,1] + *APOE*-ε4 [0,1] + Group [0: Stable, 1: aTCD] + Time [0: Baseline,1: Follow-up] + (Group [0,1] * Time [0,1]) + (1 | participant). Age was coded as a time-varying variable, accounting for the time interval between baseline and follow-up visits. Bold text indicates a significant association (*p*-values < 0.05). Aβ: β-amyloid; CSF: cerebrospinal fluid; GFAP: glial fibrillary acidic protein; NfL: neurofilament light chain; p-tau: phosphorylated tau.



Figure 1. Associations of aTCD with Fluid Biomarkers

Results from LME regression models show the main effects of group, time, and group × time interaction on longitudinal plasma and CSF biomarker outcomes, including core AD markers and biomarkers of non-specific processes involved in AD pathophysiology. Shaded areas indicate 95% confidence intervals of the predicted regression lines. Aβ: β-amyloid; AD: Alzheimer's disease; aTCD: amnestic transitional cognitive decline; CSF: cerebrospinal fluid; GFAP: glial fibrillary acidic protein; NfL: neurofilament light chain; p-tau: phosphorylated tau.

Associations of aTCD with Neuroimaging Biomarkers

Significant results were observed for the associations of aTCD with neuroimaging biomarkers. Results are presented in **Figures 2 and 3**.

Considering core AD biomarkers, aTCD was associated with higher global Aβ PET load at baseline, predominantly in frontoparietal regions, relative to the stable group. Longitudinally, aTCD showed further increases in Aβ PET load, following a similar but more localized pattern of accumulation, most prominently in the precuneus. In addition, aTCD was associated with higher tau PET load, particularly in bilateral regions of the medial temporal lobe (MTL), compared to the stable group.

Considering biomarkers of non-specific processes involved in AD pathophysiology, aTCD was associated with reduced GMv at baseline, primarily in the middle cingulate cortex, with additional, localized involvement of MTL, parietal, and frontal regions. Longitudinally, aTCD was associated with bilateral GMv reductions in the hippocampus, alongside GMv increases in neocortical regions, primarily involving right-lateralized parietal and occipital regions, with additional, localized involvement of frontal and insular areas.



Figure 2. Associations of aTCD with Neuroimaging Biomarkers: Core AD Biomarkers

Results from voxel-wise regression models show the association of aTCD with Core AD biomarkers. The figure displays brain sections following anatomical convention, where the left side of the image corresponds to the left hemisphere of the brain. Color bars indicate *T*-values, with results shown at nominal *p*-values < 0.005 accounting for a cluster-size threshold of *k* > 100 voxels. Aβ: β-amyloid; AD: Alzheimer's disease; aTCD: amnestic transitional cognitive decline; BL: baseline; FU: follow-up; PET: positron emission tomography.



Figure 3. Associations of aTCD with Neuroimaging Biomarkers: Non-specific Processes Involved in AD Pathophysiology

Results from voxel-wise regression models show the association of aTCD with biomarkers of non-specific processes involved in AD pathophysiology. The figure displays brain sections following anatomical convention, where the left side of the image corresponds to the left hemisphere of the brain. Color bars indicate *T*-values, with results shown at nominal *p*-values < 0.005 accounting for a cluster-size threshold of $k > 100$ voxels. AD: Alzheimer's disease; GMv: gray matter volume; MRI: magnetic resonance imaging; aTCD: amnestic transitional cognitive decline.

Exploratory Analysis

Significant results were observed for the associations between fluid biomarkers and longitudinal GMv change in ROIs. ROIs were defined based on post-hoc group-level contrasts, including ROIs showing longitudinal GMV reductions (bilateral hippocampus) and ROIs showing longitudinal GMV increases (neocortical regions). Results are presented in **Figure 4.**

Within the aTCD subset, higher baseline CSF p-tau181/Aβ42 ratio was associated with steeper longitudinal GMv reductions in ROIs showing longitudinal GMV reductions (β_{STD}[95%CI]= -0.369 [-0.647, -0.090]). In contrast, lower baseline plasma GFAP concentration (β_{STD}[95%CI]= -0.401 [-0.781, -0.022]) and longitudinal increase in plasma GFAP concentration (β_{STD}[95%CI]= 0.391 [-0.018, 0.764]) were both associated with steeper longitudinal GMv increments in ROIs showing longitudinal GMV increases. Full details are available in Supplementary Material.



Figure 4. Exploratory Analysis: Associations of Fluid Biomarkers with Longitudinal GMv Changes in aTCD.

Results from linear regression models show the associations between fluid biomarkers and longitudinal GMv changes in aTCD, with shaded areas representing 95% confidence intervals of the predicted regression lines. Models were adjusted for age, sex, and longitudinal time interval measured in years (in models using longitudinal biomarker data). Panel A shows the negative association between baseline CSF p-tau181/Aβ42 and GMv change in ROIs showing longitudinal GMV reductions. Panel B shows the positive association between longitudinal change in plasma GFAP and GMv change in ROIs showing longitudinal GMV increases. Mean longitudinal GMv changes by ROIs were normalized for TIV. Aβ: β-amyloid; aTCD: amnestic transitional cognitive decline; CSF: cerebrospinal fluid; GFAP: glial fibrillary acidic protein; GMv: gray matter volume; p-tau: phosphorylated tau; ROIs: regions of interest; TIV: total intracranial volume.

Discussion

This study proposed objective, standardized criteria for defining aTCD in aging and preclinical AD, supported by a comprehensive multimodal biomarker characterization. The presence of aTCD was defined through robust longitudinal neuropsychological references, applying a multivariate base rate threshold of significant cognitive decline. According to the defined criteria, 35 individuals (10% of the present sample) exhibited aTCD over a 3-year longitudinal period. Multimodal biomarker characterization demonstrated significant associations of aTCD with Core AD biomarkers, including diagnostic Core 1 AD biomarkers (higher plasma p-tau217 concentration, higher CSF p-tau181/Aβ42 ratio, and higher global Aβ PET burden) and prognostic Core 2 AD biomarkers (higher MTL tau PET burden). Additionally, significant associations of aTCD with biomarkers of non-specific processes involved in AD pathophysiology were identified, including neurodegeneration (higher plasma/CSF NfL concentrations, reduced GMv in the cingulate cortex, and longitudinal bilateral GMv reductions in the hippocampus) as well as inflammation (higher plasma/CSF GFAP concentrations and longitudinal GMv increases in neocortical regions). These findings indicate that aTCD reflects early AD-related neuropathological changes, alongside downstream mechanisms involved in AD pathophysiology, aligning with 2024 Alzheimer's Association revised criteria. This study highlights the need to strengthen current frameworks through the development of objective, standardized criteria for clinical staging, supporting early detection and risk stratification in aging and preclinical AD.

This study employed clinically grounded methods, balancing sensitivity and specificity, to define aTCD. First, the neuropsychological assessment incorporated comprehensive, standardized, and challenging episodic memory tests, encompassing the main variables from the FCSRT, MBT, and WMS-IV LM. Second, robust neuropsychological references based on AD biomarkers, which measured deviation relative to the group with nonpathological biomarker levels, enhanced sensitivity for detecting subtle cognitive decline in preclinical AD.[29,49] The outcome of a neuropsychological assessment depends on the normative references applied, with growing evidence indicating that robust normative frameworks provide higher diagnostic standards than conventional references.[21,22] Third, the use of demographically adjusted complex SRB longitudinal change indices, reflecting deviation from normative intra-individual cognitive variability over time, allowed to apply a cut-off consistent with clinical practice to define statistically significant longitudinal decline at the variable level (*i.e.*, SRB change ≤ 5th percentile). Neuropsychological methods that track change relative to an individual's baseline are essential, as cross-sectional assessments may be insufficient for detecting significant cognitive decline, particularly in the absence of clinical impairment. Within this framework, SRB models have been proposed as a sensitive approach for defining TCD,[32] and have been previously validated in both MCI and dementia stages.[34] Fourth, the accuracy and stability of MCI diagnoses, considering progression and conversion rates, depend on the number of impaired neuropsychological measurements required and the specific cut-offs employed to define impairment.[50] This is particularly important at earlier stages, where distinguishing transitional decline from normal aging is more challenging, highlighting the need for careful methodological approaches that account for these factors. To define aTCD, this was addressed through a multivariate base rate threshold of significant cognitive decline, controlling false-positive classifications.[31]

To examine the relationship with Core AD biomarkers, the associations between aTCD and multimodal biomarkers of Aβ and tau were evaluated. aTCD was significantly associated with fluid biomarkers, including higher plasma p-tau217 concentration and CSF p-tau181/Aβ42 ratio. Beyond the significant main group effect, both biomarker levels showed significant longitudinal increases across the full sample, with plasma p-tau217 exhibiting the greatest rise. However, only CSF p-tau181/Aβ42 demonstrated a significant group × time interaction, indicating greater longitudinal change in aTCD. While the pronounced rise in plasma p-tau217 indicated widespread early AD-related changes across the full sample, the longitudinal increase in the CSF p-tau181/Aβ42 ratio, which specifically tracked the memory decline characteristic of aTCD, suggested a more direct link with clinical Stage 2. These results were consistent with previous studies linking Core AD pathology with cognitive decline in CU population.[51–53] Additionally, aTCD was significantly associated with neuroimaging biomarkers, including higher Aβ and tau PET load. Baseline Aβ PET load was significantly higher in aTCD, demonstrating greater global burden, with prominent deposition in frontoparietal brain regions. Longitudinally, aTCD showed significant increases in Aβ PET load, following a similar but more localized pattern of accumulation, most notably in the precuneus. Tau PET load, acquired only at follow-up, was also significantly higher in aTCD, demonstrating greater burden in bilateral MTL regions. These results were consistent with Aβ and tau staging in AD, implicating regions typically affected during the early to intermediate phases of Aβ progression[54] and aligning with early MTL–restricted tau accumulation characteristic of clinical Stage 2, prior to widespread neocortical involvement and overt clinical impairment.[5,55]

To examine the relationship with non-specific processes involved in AD pathophysiology, the associations between aTCD and multimodal biomarkers of neurodegeneration and inflammation were evaluated. aTCD was significantly associated with fluid biomarkers, including higher neurodegeneration levels, measured by plasma and CSF NfL concentrations, as well as higher inflammation levels, measured by plasma and CSF GFAP concentrations. Beyond the significant main group effect, all these biomarker levels showed significant longitudinal increases across the full sample, with plasma GFAP exhibiting the greatest rise, but no significant group × time interaction. These results were consistent with previous research, showing that neurodegenerative and inflammatory mechanisms involved in AD pathophysiology are associated with cognitive decline in CU population.[56,57] Additionally, aTCD was significantly associated with neuroimaging biomarkers, showing differences in GMv. At baseline, aTCD was associated with reduced GMv, primarily in the middle cingulate cortex. Longitudinally, it was associated with bilateral GMv reductions in the hippocampus and GMv increases in neocortical regions. These results were consistent with the early vulnerability of the hippocampus in AD, supporting the objective characterization of aTCD as a subclinical amnestic syndrome.[58,59] Although, to the best of our knowledge, GMv reduction in the cingulate cortex has not been previously reported in preclinical AD, regional vulnerability may emerge earlier than previously recognized, consistent with reports of cingulate atrophy in MCI.[60,61] Likewise, the observed longitudinal GMv increases in neocortex, although not well established in current frameworks, align with growing evidence describing non-linear structural dynamics across the preclinical stage of AD.[62–65]

Exploratory analyses examined potential mechanisms underlying longitudinal GMv changes in aTCD. Results revealed a complex pattern of associations: the CSF p-tau181/Aβ42 ratio was associated with longitudinal GMv reductions in the bilateral hippocampus, whereas plasma GFAP concentration was associated with longitudinal GMv increases in the neocortex. These findings suggest that Core AD pathology contributes to the neurodegenerative mechanisms underlying the subclinical amnestic syndrome characterized by aTCD, consistent with evidence linking episodic memory decline to Aβ-related hippocampal atrophy.[66] Although the exact role of plasma GFAP in reflecting astrocytic reactivity remains uncertain, despite its greater sensitivity than CSF GFAP,[67] these results suggest that longitudinal GMv increases in neocortical regions may reflect transient morphological changes, potentially arising as an early inflammatory response to Aβ pathology.[68,69] Nevertheless, further studies are needed to clarify the mechanisms linking pathological processes to structural brain alterations in aging and preclinical AD, particularly in relation to the emergence of subclinical manifestations.

Several aspects require further development to translate these findings into clinical practice, including validation across independent cohorts. First, the prognostic value of the proposed criteria should be determined with longer follow-up. Importantly, the operational definition of MCI, which delineates the boundary of TCD, directly influences prevalence estimates and prognostic interpretation. Second, the prevalence of TCD across additional domains (*e.g.*, dysexecutive, linguistic, mixed variants) should be determined in future studies, as cognitive phenotyping to distinguish MCI subtypes has been linked to the diagnostic performance of AD biomarkers.[70] Third, clinical staging and diagnostic criteria should address metacognitive assessment to ensure conceptual alignment with the natural course of the disease.[71] In this study, individuals exhibiting aTCD demonstrated substantial heterogeneity in cognitive awareness (*i.e.*, > 40% of aTCD did not report SCD at follow-up), suggesting the emergence of subclinical amnestic anosognosia. This finding underscores a key limitation of self-reported SCD for defining Stage 2, a critical yet often neglected clinical aspect. Previous studies have demonstrated that self-reported SCD contributes to MCI misdiagnosis,[72] while anosognosia is associated with clinical progression across the AD *continuum*.[11,73] Fourth, clinical staging in 2024 Alzheimer's Association revised criteria was based on biologically confirmed AD diagnoses, but the present study defined aTCD without requiring a positive Core 1 AD biomarker (60% of aTCD were Aβ-positive at baseline). This is consistent with previous studies showing that subthreshold levels of Aβ pathology were associated with episodic memory decline in the CU population,[74] and not all individuals follow a canonical temporal sequence of biological and clinical events.[75] Indeed, 2024 guidelines acknowledge considerable individual variability, highlighting the need for further research on vulnerability and resilience mechanisms, as well as comorbid pathologies.

In conclusion, this study proposed objective, standardized criteria for defining aTCD using robust longitudinal neuropsychological references with multivariate base rate thresholds of significant cognitive decline. Comprehensive multimodal biomarker characterization revealed significant associations with Core AD biomarkers and biomarkers of non-specific processes involved in AD pathophysiology. These findings underscore the need to strengthen current frameworks through the development of standardized clinical staging criteria, supporting early detection and risk stratification in aging and preclinical AD.

References

1. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: Stopping AD before symptoms begin? *Sci Transl Med*. 2014;6(228). doi:10.1126/scitranslmed.3007941

2. Boxer AL, Sperling R. Accelerating Alzheimer's therapeutic development: The past and future of clinical trials. *Cell.Elsevier B.V.* 2023;186(22):4757-4772. doi:10.1016/j.cell.2023.09.023

3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's and Dementia*. 2011;7(3):280-292. doi:10.1016/j.jalz.2011.03.003

4. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's and Dementia.Elsevier Inc.* 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018

5. Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimers Dement*. Published online June 27, 2024. doi:10.1002/alz.13859

6. Grober E, Lipton RB, Sperling RA, et al. Associations of Stages of Objective Memory Impairment with Amyloid PET and Structural MRI: The A4 Study. *Neurology*. 2022;98(13):E1327-E1336. doi:10.1212/WNL.0000000000200046

7. Grober E, Petersen KK, Lipton RB, et al. Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals. *Neurology*. 2023;100(22):E2279-E2289. doi:10.1212/WNL.0000000000207276

8. Insel PS, Donohue MC, Sperling R, Hansson O, Mattsson-Carlgren N. The A4 study: β-amyloid and cognition in 4432 cognitively unimpaired adults. *Ann Clin Transl Neurol*. 2020;7(5):776-785. doi:10.1002/acn3.51048

9. Cacciamani F, Houot M, Gagliardi G, et al. Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. *Front Aging Neurosci.Frontiers Media S.A.* 2021;13. doi:10.3389/fnagi.2021.697234

10. López-Martos D, Suárez-Calvet M, Milà-Alomà M, et al. Awareness of episodic memory and meta-cognitive profiles: associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer's continuum. *Front Aging Neurosci*. 2024;16. doi:10.3389/fnagi.2024.1394460

11. Hanseeuw BJ, Scott MR, Sikkes SAM, et al. Evolution of anosognosia in alzheimer's disease and its relationship to amyloid. *Ann Neurol*. 2020;87(2):267-280. doi:10.1002/ana.25649

12. Dubois B, Villain N, Schneider L, et al. Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation. *JAMA Neurol*. Published online November 1, 2024. doi:10.1001/jamaneurol.2024.3770

13. Kiselica AM, Atkins KJ, Han SD, et al. Reactions of clinical neuropsychologists to the Alzheimer's Association workgroup's draft diagnostic and staging criteria for Alzheimer's disease. *J Alzheimers Dis*. 2024;102(3):877-884. doi:10.1177/13872877241292089

14. Kiselica AM, Gaynor LS, Atkins KJ. IWG and AA Criteria—Where the Differences Matter. *JAMA Neurol*. Published online April 21, 2025. doi:10.1001/jamaneurol.2025.0775

15. Thomas KR, Edmonds EC. Objective Criteria for Subtle Cognitive Decline in Aging and Preclinical Alzheimer Disease: A Systematic Review. *Neurology*. 2025;104(9):e213536.

16. Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of Amyloid and Tau with Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. *JAMA Neurol*. 2019;76(8):915-924. doi:10.1001/jamaneurol.2019.1424

17. Papp K V., Buckley R, Mormino E, et al. Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. *Alzheimer's and Dementia*. 2020;16(3):552-560. doi:10.1016/j.jalz.2019.09.074

18. Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner M, Aisen PS. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. *JAMA - Journal of the American Medical Association*. 2017;317(22):2305-2316. doi:10.1001/jama.2017.6669

19. Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. *Nat Med*. 2022;28(11):2381-2387. doi:10.1038/s41591-022-02049-x

20. Kiselica AM, Karr JE, Mikula CM, et al. Recent Advances in Neuropsychological Test Interpretation for Clinical Practice. *Neuropsychol Rev*.*Springer*. 2024;34(2):637-667. doi:10.1007/s11065-023-09596-1

21. Bos I, Vos SJB, Jansen WJ, et al. Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. *Front Aging Neurosci*. 2018;10. doi:10.3389/fnagi.2018.00193

22. Hassenstab J, Chasse R, Grabow P, et al. Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. *Neurobiol Aging*. 2016;43:23-33. doi:10.1016/j.neurobiolaging.2016.03.014

23. Harrington KD, Lim YY, Ames D, et al. Using robust normative data to investigate the neuropsychology of cognitive aging. *Archives of Clinical Neuropsychology*. 2017;32(2):142-154. doi:10.1093/arclin/acw106

24. Kaser AN, Kaplan DM, Goette W, Kiselica AM. The impact of conventional versus robust norming on cognitive characterization and clinical classification of MCI and dementia. *J Neuropsychol*. 2023;17(1):108-124. doi:10.1111/jnp.12289

25. Duff K. Current topics in science and practice evidence-based indicators of neuropsychological change in the individual patient: Relevant concepts and methods. *Archives of Clinical Neuropsychology*. 2012;27(3):248-261. doi:10.1093/arclin/acr120

26. Duff K, Atkinson TJ, Suhrie KR, Dalley BCA, Schaefer SY, Hammers DB. Short-term practice effects in mild cognitive impairment: Evaluating different methods of change. *J Clin Exp Neuropsychol*. 2017;39(4):396-407. doi:10.1080/13803395.2016.1230596

27. Duff K, Dixon AM, Embree L, Hoffman JM. Change on the Repeatable Battery for the Assessment of Neuropsychological Status and its relationship to brain amyloid. *J Clin Exp Neuropsychol*. 2023;45(2):105-117. doi:10.1080/13803395.2023.2216920

28. Borland E, Edgar C, Stomrud E, Cullen N, Hansson O, Palmqvist S. Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials. *Neurology*. 2022;99(11):E1142-E1153. doi:10.1212/WNL.0000000000200817

29. López-Martos D, Brugulat-Serrat A, Suárez-Calvet M, et al. Robust Longitudinal Neuropsychological Norms in Spanish Individuals With Nonpathological Alzheimer's Disease Biomarkers. *Neuropsychology*. Published online 2025. doi:10.1037/neu0001013

30. Brooks BL, Iverson GL, White T. Substantial risk of "Accidental MCI" in healthy older adults: Base rates of low memory scores in neuropsychological assessment. *Journal of the International Neuropsychological Society*. 2007;13(3):490-500.

31. Kiselica AM, Webber TA, Benge JF. Using multivariate base rates of low scores to understand early cognitive declines on the uniform data set 3.0 Neuropsychological Battery. *Neuropsychology*. 2020;34(6):629.

32. Kiselica AM, Kaser AN, Webber TA, Small BJ, Benge JF. Development and Preliminary Validation of Standardized Regression-Based Change Scores as

Measures of Transitional Cognitive Decline. *Archives of Clinical Neuropsychology*. Published online March 10, 2025. doi:10.1093/arclin/acaf015

33. Oltra-Cucarella J, Sánchez-SanSegundo M, Rubio-Aparicio M, Arango-Lasprilla JC, Ferrer-Cascales R. The Association Between the Number of Neuropsychological Measures and the Base Rate of Low Scores. *Assessment*. 2021;28(3):955-963. doi:10.1177/1073191119864646

34. Duff K, Sevigny-Resetco D. Validation of regression-based change formulae for mild cognitive impairment and Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*. 2024;16(3). doi:10.1002/dad2.70008

35. Molinuevo JL, Gramunt N, Gispert JD, et al. The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*. 2016;2(2):82-92. doi:10.1016/j.trci.2016.02.003

36. Milà-Alomà M, Salvadó G, Gispert JD, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. *Alzheimer's and Dementia*. 2020;16(10):1358-1371. doi:10.1002/alz.12131

37. Suárez-Calvet M, Karikari TK, Ashton NJ, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's *continuum* when only subtle changes in Aβ pathology are detected. *EMBO Mol Med*. 2020;12(12). doi:10.15252/emmm.202012921

38. Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. *Lancet Neurol*. 2021;20(9):739-752. doi:10.1016/S1474-4422(21)00214-3

39. Shekari M, Vállez García D, Collij LE, et al. Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology. *Alzheimer's and Dementia*. 2024;20(8):5102-5113. doi:10.1002/alz.13883

40. Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage*. 2007;38(1):95-113.

41. Good CD, Johnsrude IS, Ashburner J, Henson RNA, Friston KJ, Frackowiak RSJ. A voxel-based morphometric study of ageing in 465 normal adult human brains. *Neuroimage*. 2001;14(1):21-36.

42. Peña-Casanova J, Gramunt-Fombuena N, Quiñones-Úbeda S, et al. Spanish multicenter normative studies (NEURONORMA project): Norms for the rey-osterrieth complex figure (copy and memory), and free and cued selective reminding test. *Archives of Clinical Neuropsychology*. 2009;24(4):371-393. doi:10.1093/arclin/acp041

43. Gramunt N, Sánchez-Benavides G, Buschke H, et al. The Memory Binding Test: Development of Two Alternate Forms into Spanish and Catalan. *Journal of Alzheimer's Disease*. 2016;52(1):283-293. doi:10.3233/JAD-151175

44. Wechsler D. *Wechsler Memory Scale-IV. Spanish Edition*. Pearson Clinical & Talent Assessment; 2013.

45. Morris JC. The Clinical Dementia Rating (CDR) current version and scoring rules. *Neurology*. 1993;43(11):2412.

46. Blesa R, Pujol M, Aguilar M, et al. Clinical validity of the 'mini-mental state'for Spanish speaking communities. *Neuropsychologia*. 2001;39(11):1150-1157.

47. Rami L, Mollica MA, Garcfa-Sanchez C, et al. The subjective cognitive decline questionnaire (SCD-Q): A validation study. *Journal of Alzheimer's Disease*. 2014;41(2):453-466. doi:10.3233/JAD-132027

48. Jak AJ, Bondi MW, Delano-Wood L, et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. *American Journal of Geriatric Psychiatry*. 2009;17(5):368-375. doi:10.1097/JGP.0b013e31819431d5

49. López-Martos D, Suárez-Calvet M, Milà-Alomà M, et al. Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease. *Neurology*. 2025;105(9). doi:10.1212/WNL.0000000000214308

50. Simone G, Michele R, Federica DS, Giulia L, Antonio G, Elena R. Conventional and neuropsychological criteria for mild cognitive impairment show similar prognostic value for dementia across 12 years in a non-clinical setting. *Sci Rep*. 2025;15(1):19827. doi:10.1038/s41598-025-04275-y

51. Ossenkoppele R, Salvadó G, Janelidze S, et al. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. *Nat Aging*. Published online 2025. doi:10.1038/s43587-025-00835-z

52. Mattsson-Carlgren N, Salvadó G, Ashton NJ, et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. *JAMA Neurol*. 2023;80(4):360-369. doi:10.1001/jamaneurol.2022.5272

53. Long JM, Coble DW, Xiong C, et al. Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes. *Brain*. 2022;145(12):4506-4518.

54. Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging β -Amyloid Pathology with Amyloid Positron Emission Tomography. *JAMA Neurol*. 2019;76(11):1319-1329. doi:10.1001/jamaneurol.2019.2214

55. Therriault J, Schindler SE, Salvadó G, et al. Biomarker-based staging of Alzheimer disease: rationale and clinical applications. *Nat Rev Neurol*. 2024;20(4):232-244.

56. Mielke MM, Syrjanen JA, Blennow K, et al. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. *Neurology*. 2019;93(3):e252-e260.

57. Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. *Brain*. 2021;144(11):3505-3516. doi:10.1093/brain/awab223

58. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol*. 2013;12(2):207-216.

59. Jack CR, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. *Neurology*. 2000;55(4):484-490. doi:10.1212/WNL.55.4.484

60. Susanto TAK, Pua EPK, Zhou J. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of alzheimer's disease and the influence of apolipoprotein E. *Journal of Alzheimer's Disease*. 2015;45(1):253-268. doi:10.3233/JAD-142451

61. Pengas G, Hodges JR, Watson P, Nestor PJ. Focal posterior cingulate atrophy in incipient Alzheimer's disease. *Neurobiol Aging*. 2010;31(1):25-33.

62. Gispert JD, Rami L, Sánchez-Benavides G, et al. Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. *Neurobiol Aging*. 2015;36(10):2687-2701.

63. Fortea J, Sala-Llonch R, Bartrés-Faz D, et al. Cognitively preserved subjects with transitional cerebrospinal fluid ss-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. *Biol Psychiatry*. 2011;70(2):183-190.

64. Fortea J, Vilaplana E, Alcolea D, et al. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. *Ann Neurol*. 2014;76(2):223-230.

65. Pegueroles J, Vilaplana E, Montal V, et al. Longitudinal brain structural changes in preclinical Alzheimer's disease. *Alzheimer's & Dementia*. 2017;13(5):499-509.

66. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated β-amyloid deposition in elderly subjects. *Brain*. 2009;132(5):1310-1323. doi:10.1093/brain/awn320

67. Youn W, Yun M, Lee CJ, Schöll M. Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases. *Molecular Neurodegeneration* . 2025;20(1). doi:10.1186/s13024-025-00846-9

68. Salvadó G, Shekari M, Falcon C, et al. Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers. *Brain Commun*. 2022;4(3). doi:10.1093/braincomms/fcac134

69. Salvadó G, Milà-Alomà M, Shekari M, et al. Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum. *Eur J Nucl Med Mol Imaging*. 2022;49(13):4567-4579. doi:10.1007/s00259-022-05897-4

70. Bouteloup V, Villain N, Vidal JS, et al. Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers. *JAMA Neurol*. Published online April 4, 2025. doi:10.1001/jamaneurol.2025.0142

71. Cappa SF, Ribaldi F, Chicherio C, Frisoni GB. Subjective cognitive decline: Memory complaints, cognitive awareness, and metacognition. *Alzheimer's and Dementia*. Published online September 1, 2024. doi:10.1002/alz.13905

72. Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. *Journal of the International Neuropsychological Society*. 2014;20(8):836-847. doi:10.1017/S135561771400068X

73. Therriault J, Ng KP, Pascoal TA, et al. Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. *Neurology*. 2018;90(11):e932-e939.

74. Landau SM, Horng A, Jagust WJ. Memory decline accompanies subthreshold amyloid accumulation. *Neurology*. 2018;90(17):E1452-E1460. doi:10.1212/WNL.0000000000005354

75. Edmonds EC, Delano-Wood L, Galasko DR, Salmon DP, Bondi MW. Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2015;47(1):231-242. doi:10.3233/JAD-150128

Acknowledgments

This publication is part of the ALFA study. The authors would like to express their most sincere gratitude to the ALFA project participants and relatives without whom this research would not have been possible. The authors also thank Roche Diagnostics International Ltd for providing the kits used to measure CSF biomarkers, the laboratory technicians at the Clinical Neurochemistry Laboratory in Mölndal, Sweden, for performing the analyses, GE Healthcare for supplying the [^{18}F]flutemetamol doses, F. Hoffmann-La Roche Ltd for sponsoring the tau PET study, and Eli Lilly and Company for providing the measurements of the in-house assay for plasma p-tau217.

COBAS and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). The Elecsys β-Amyloid(1–42) CSF and Elecsys Phospho-Tau (181P) CSF assays are approved for clinical use.

Collaborators of the ALFA study are: Federica Anastasi, Annabella Beteta, Marta del Campo, Lidia Canals, Alba Cañas, Irene Cumplido-Marinero, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Karine Fauria, Ana Fernández-Angulo, Sherezade Fuentes, Marina García, Patricia Genius, Armand González-Escolar, Laura Hernández, Felipe Hernández-Viadel, Gema Huesa, Jordi Huguet, Laura Iglesias, Esther Jiménez, Ferran Lugo, Paula Marne, Tania Menchón, José Luis Molinuevo, Paula Ortiz-Romero, Wiesje Pelkmans, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernández, Iman Sadeghi, Lluís Solsona, Anna Soteras, Laura Stankeviciute, Núria Tort-Colet, Marc Vilanova, Natalia Vilor-Tejedor.

Funding

The research leading to these results has received funding from “la Caixa” Foundation under agreement LCF/PR/SC22/68000001, the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). RC received funding from the MCIN/AEI/10.13039/501100011033/FEDER, EU, through the project PID2021-125433OA-100 and from the grant RYC2021-031128-I, funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR; MS-C received funding from the ERC under the EU’s Horizon 2020 research and innovation program (grant no. 948677), ERA PerMed-ERA NET and the Generalitat de Catalunya (Departament de Salut) through project no. SLD077/21/000001, projects PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the EU (FEDER), and from a fellowship from ‘la Caixa’ Foundation (ID 100010434) and the EU’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (grant no. 847648 (LCF/BQ/PR21/11840004)); AB-S received funding from the Alzheimer's Association Clinician Scientist Fellowship (AACSF) Program, through the grant AACSF-23-1145154; HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union’s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer’s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rönströms Stiftelse, Familjen Beiglers Stiftelse, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (UKDRI-1003), and an anonymous donor; KB is supported by the Swedish Research Council (#2017-00915 and #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, and #AF-994551), Hjärnfonden, Sweden (#ALZ2022-0006, #FO2024-0048-TK-130 and FO2024-0048-HK-24), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-965240 and #ALFGBG-1006418), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer’s Association 2021 Zenith Award (ZEN-21-848495), the Alzheimer’s Association 2022-2025 Grant (SG-23-1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and Freddy Johansen Foundation, Copenhagen, Denmark, Familjen Rönströms Stiftelse, Stockholm, Sweden, and an anonymous filantropist and donor; JDG was supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054), received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from

Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261); OG-R was supported by the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva program IJC2020-043417-I), funded by MCIN/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR, Instituto de Salud Carlos III (ISCIII) through the projects "PI19/00117" and "PI24/00116" and co-funded by the European Union/FEDER. OG-R also receives funding from F. Hoffmann-La Roche Ltd, and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U; GS-B was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union/FSE+, supported by MCIN/AEI/10.13039/501100011033, through the project PID2020-119556RA-I00 and grant CP23/00039.

Conflicts of Interest

DL-M, RC, MS, AG-E, MM-A, AB-S, and CM have nothing to disclose; MS-C has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and Grifols S.L., has given lectures in symposia sponsored by Roche Diagnostics, S.L.U and Roche Farma, S.A., and was granted with a project funded by Roche Diagnostics International Ltd; GS has received speaker fees from Springer, GE Healthcare, Biogen, Esteve and Adium and she serves on the advisory board of Johnson&Johnson; MT is a full-time employee and own stock in F. Hoffmann-La Roche Ltd; EB was a full-time employee in F. Hoffmann-La Roche Ltd; GK is a full-time employee and own stock in F. Hoffmann-La Roche Ltd; CQ-R is a full-time employee of Roche Diagnostics International Ltd, Rotkreuz, Switzerland; GK is a full-time employee of Roche Diagnostics GmbH, Penzberg, Germany; HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of MicThera (outside submitted work); KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sunbird Bio, Sanofi and Siemens Healthineers, has served at data monitoring committees for Julius Clinical and Novartis, has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper; JDG receives research funding from Roche Diagnostics and GE Healthcare and has given lectures at symposia sponsored by Biogen and Philips; OG-R receives research funding from Roche Pharma; GS-B worked as a consultant for Roche Farma, S.A.